[{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Agreement","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":1.1299999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":1.1299999999999999,"dosageForm":"Intrathecal Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Axatilimab","moa":"Macrophage colony stimulating factor receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Geron","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Financing","leadProduct":"Imetelstat","moa":"Telomerase reverse transcriptase","graph1":"Oncology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.25,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Intravenous Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"ImmuNext Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Frexalimab","moa":"TNFSF5","graph1":"Neurology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Nadofaragene Firadenovec","moa":"IFNA2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.5,"dosageForm":"Intravesical Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Blueprint Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Pralsetinib","moa":"Coiled-coil domain-containing protein 6\/Tyrosine-protein kinase receptor RET | Tyrosine-protein kinase receptor RET | Kinesin-1 heavy chain\/ Tyrosine-protein kinase receptor RET","graph1":"Oncology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.34000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.34000000000000002,"dosageForm":"Oral Capsule","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Cabozantinib","moa":"Vascular endothelial growth factor receptor 2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.39000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.39000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"PTC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":1.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":1.5,"dosageForm":"Oral Solution","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Theravance Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Steroid","year":"2022","type":"Divestment","leadProduct":"Fluticasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":1.55,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.55,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"AiCuris","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Letermovir","moa":"DNA terminase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.22,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.22,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Karuna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Xanomeline","moa":"||Muscarinic acetylcholine receptor M1 | Muscarinic acetylcholine receptor M4","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.5,"dosageForm":"Oral Capsule","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Daraxonrasib","moa":"RAS","graph1":"Oncology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":1.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":1.25,"dosageForm":"Oral Capsule","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Minerva Neurosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Seltorexant","moa":"Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.16,"dosageForm":"Oral Tablet","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Cytokinetics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Aficamten","moa":"MYH6_7","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Cytokinetics","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Omecamtiv Mecarbil","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.45000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Vorasidenib","moa":"IDH1\/IDH2","graph1":"Oncology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.91000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.91000000000000003,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"PTC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.65000000000000002,"dosageForm":"Oral Solution","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"MorphoSys","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"GERMANY","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Immunology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":2.0299999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":2.0299999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2023","type":"Financing","leadProduct":"Lonapegsomatropin","moa":"Growth hormone receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.14999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Dicerna Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Acquisition","leadProduct":"Lumasiran","moa":"Hydroxyacid oxidase 1 mRNA","graph1":"Rare Diseases and Disorders","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.23999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Rare Diseases","amount2New":0.23999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Palopegteriparatide","moa":"PTH1R","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.14999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Collaboration","leadProduct":"Litifilimab","moa":"C-type lectin domain family 4 member C","graph1":"Immunology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.25,"dosageForm":"Subcutaneous Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Subcutaneous Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"Olpasiran","moa":"LPA mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.40999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Olpasiran","moa":"LPA mRNA","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Royalty Pharma","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.40999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Acquisition","leadProduct":"Vedolizumab","moa":"Integrin alpha-4\/beta-7","graph1":"Immunology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.33000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Zavegepant HCl","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.47999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.47999999999999998,"dosageForm":"Nasal Spray","sponsorNew":"Royalty Pharma \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Pfizer Inc"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Vorasidenib","moa":"IDH1\/IDH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.91000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.91000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Ivacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.65000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Zavegepant HCl","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Royalty Pharma","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.45000000000000001,"dosageForm":"Nasal Spray","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Royalty Pharma \/ Royalty Pharma"},{"orgOrder":0,"company":"Royalty Pharma","sponsor":"BeOne Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Tarlatamab","moa":"DLL3","graph1":"Oncology","graph2":"Approved FDF","graph3":"Royalty Pharma","amount2":0.94999999999999996,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.94999999999999996,"dosageForm":"Infusion","sponsorNew":"Royalty Pharma \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Royalty Pharma \/ Royalty Pharma"}]
Find Clinical Drug Pipeline Developments & Deals by Royalty Pharma
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
